FACTBOX-Developers of potential Ebola vaccines and treatments

Aug 11 (Reuters) - Several companies with potential Ebola
vaccines and treatments have captured the spotlight, as
developers face mounting pressure to expedite research on new
medical interventions.

The Ebola epidemic in West Africa has killed nearly 1,000
people and prompted the World Health Organization to declare an
international health emergency.

No Ebola drugs or vaccines have entered mid-stage human
trials, let alone been approved. The most advanced have been
tested only in monkeys and a handful of humans.

VACCINES

GLAXOSMITHKLINE PLC

GSK is co-developing a vaccine with the U.S. National
Institute of Allergy and Infectious Diseases (NIAID), which has
shown promising results in primates.

The vaccine is due to enter early-stage human trials,
pending U.S. Food and Drug Administration approval. GSK has said
human testing should start this year. NIAID expects trials to
begin "as early as fall 2014."

Even if it is fast-tracked and works as well as hoped, the
new vaccine could not be ready for widespread deployment before
2015.
Continued...